David Sidransky's most recent trade in Champions Oncology Inc was a trade of 21,880 Option to purchase Common Stock done . Disclosure was reported to the exchange on Nov. 12, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Champions Oncology Inc | David Sidransky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Nov 2024 | 21,880 | 21,880 | - | - | Option to purchase Common Stock | |
| Orgenesis Inc | Sidransky David | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Dec 2023 | 20,450 | 20,450 | - | - | Stock Option | |
| Champions Oncology Inc | David Sidransky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Nov 2023 | 15,495 | 15,495 | - | - | Option to purchase Common Stock | |
| Orgenesis Inc | David Sidransky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2022 | 20,450 | 20,450 | - | - | Stock Option | |
| Champions Oncology Inc | David Sidransky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2022 | 11,480 | 11,480 | - | - | Option to purchase Common Stock | |
| Champions Oncology Inc | David Sidransky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Oct 2022 | 8,333 | 0 | - | - | Option to purchase Common Stock | |
| Champions Oncology Inc | David Sidransky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.21 per share. | 12 Oct 2022 | 8,333 | 770,605 (6%) | 0% | 3.2 | 26,749 | Common Stock |
| Champions Oncology Inc | David Sidransky | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.51 per share. | 12 Oct 2022 | 3,562 | 767,043 (6%) | 0% | 7.5 | 26,751 | Common Stock |
| Champions Oncology Inc | David Sidransky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Oct 2021 | 16,667 | 0 | - | - | Option to purchase Common Stock | |
| Champions Oncology Inc | David Sidransky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.59 per share. | 15 Oct 2021 | 16,667 | 764,901 (6%) | 0% | 1.6 | 26,501 | Common Stock |
| Champions Oncology Inc | David Sidransky | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.08 per share. | 15 Oct 2021 | 2,629 | 762,272 (6%) | 0% | 10.1 | 26,500 | Common Stock |
| Champions Oncology Inc | David Sidransky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2020 | 8,333 | 8,333 | - | - | Option to purchase Common Stock | |
| Champions Oncology Inc | David Sidransky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.46 per share. | 16 Oct 2020 | 16,667 | 758,334 (6%) | 0% | 5.5 | 91,002 | Common Stock |
| Champions Oncology Inc | David Sidransky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Oct 2020 | 16,667 | 0 | - | - | Option to purchase Common Stock | |
| Champions Oncology Inc | David Sidransky | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.01 per share. | 16 Oct 2020 | 10,100 | 748,234 (6%) | 0% | 9.0 | 91,001 | Common Stock |